Skip to main content

Research

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Sep. 13, 2022—Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

Read more


Cancer registries and sarcoma research

Sep. 13, 2022—The number of sarcoma research studies that use the two largest U.S. cancer registries is increasing, but over one-third of studies that asked the same research question reported conflicting findings.

Read more


Enhancing innate immunity in the lung

Sep. 12, 2022—Vanderbilt researchers show that a TLR4 agonist improves lung immune response and survival in a mouse model of bacterial pneumonia, supporting the development of this drug to protect against pneumonia in hospitalized patients.

Read more


PheWAS reveals post-COVID-19 diagnoses

Sep. 8, 2022—Using a high-throughput informatics technique and electronic health records, Vanderbilt researchers found that COVID-19 survivors had an increased risk for more than 40 new diagnoses.

Read more


Immune cells drive beta cell loss in Type 2 diabetes

Sep. 8, 2022—Vanderbilt researchers have discovered details of pancreatic beta cell loss — and potential therapeutic targets — during conditions of overnutrition, as occurs in obesity.

Read more


Study identifies key player in T cell “education”

Sep. 1, 2022—New Vanderbilt research could inform therapeutic strategies for enhancing thymic function when desired — such as during aging, recovery from radiation therapy or chemotherapy, or other conditions that reduce T cell output.

Read more


A new mechanism for lupus

Aug. 30, 2022—Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.

Read more


Blood cancer progression

Aug. 29, 2022—Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.

Read more


New high-tech biobank safeguards critical specimens

Aug. 25, 2022—by Bill Snyder Vanderbilt University Medical Center has opened a state-of-the-art automated biobanking system that can store as many as 10 million biospecimens, including blood and body fluids, tissue, and genetic and protein material, at temperatures down to minus 80 degrees Celsius. The “BioStore” was purchased from its manufacturer, Massachusetts-based Azenta Life Sciences, with the...

Read more


Vanderbilt researchers discover how gut inflammation leads to bone loss

Aug. 25, 2022—Gastrointestinal inflammation, such as occurs in inflammatory bowel disease, triggers the expansion of a population of “bone-eating” cells, leading to bone loss.

Read more


Study describes how E. coli co-opts cells, causes recurrent UTIs

Aug. 25, 2022—Researchers at Vanderbilt University Medical Center have discovered why the uropathogenic bacterium E. coli, the leading cause of urinary tract infections, is so tenacious; their findings could lead to new ways to prevent recurrent UTIs.

Read more


Rheumatoid arthritis and heart disease: a common path

Aug. 25, 2022—An increase in certain antibodies in patients with rheumatoid arthritis can serve as a predictive biomarker for cardiovascular disease, Vanderbilt researchers have discovered.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more